Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...

On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options ...